Cronos to acquire CanAdelaar for 57.5 million euros

Executive Summary

• Cronos Group Inc. has entered into a definitive agreement to acquire CanAdelaar BV, the largest cannabis company operating within the Netherlands' adult-use cannabis pilot program (the Wietexperiment), establishing a strategic footprint in Europe.
• The transaction involves an upfront cash consideration of €57.5 million ($67.0 million USD), plus contingent consideration based on 0.5 times normalized EBITDA for 2026 and 2027.
• The acquisition provides Cronos with an industrial-scale greenhouse cultivation facility, leading market share in the Dutch pilot program, and a platform for its "borderless product strategy" including edibles, vapes, and prerolls.

Key Details

• Transaction Structure: Definitive share sale and purchase agreement to acquire 100% of outstanding shares of CanAdelaar BV.
• Upfront Consideration: €57.5 million (approximately $67.0 million USD), subject to customary adjustments.
• Contingent Consideration: Cash payments equal to 0.5 times CanAdelaar's normalized EBITDA for the years 2026 and 2027.
• Valuation Metrics: The upfront consideration represents approximately 1.4 times LTM revenue and 2.4 times LTM EBITDA.
• Closing Timeline: Expected to close in early 2026, subject to customary closing conditions and regulatory clearances in the Netherlands.
• Target Profile (CanAdelaar BV):
  • Largest cannabis company in the Netherlands' Wietexperiment (adult-use pilot program).
  • Operates a 540,000-square-foot facility in Voorne aan Zee, Netherlands, featuring greenhouse cultivation, processing, production, and packaging.
  • Only industrial-scale greenhouse cultivator among the 10 licensed producers in the pilot program (others use indoor facilities).
  • Active sales to nearly all 72 coffee shops within the 10 participating municipalities.
• Financial Performance of Target:
  • Revenue: $17.7 million USD in 2024; $47.3 million USD for the 12 months ended Sept. 30, 2025.
  • EBITDA: $8.0 million USD in 2024; $28.2 million USD for the 12 months ended Sept. 30, 2025.
  • Current cultivation yield: Approximately 20,000 kilograms of dried flower annually.
• Strategic Rationale:
  • Enables Cronos's "borderless product strategy" by leveraging investments in genetics and product development (edibles, vapes, prerolls, hash) beyond just flower.
  • Provides a competitive cost position due to greenhouse cultivation efficiency.
  • Offers upside potential if the Wietexperiment expands beyond the current 10 municipalities to nationwide coverage.
• Regulatory Context: The Wietexperiment is a four-year pilot program (launched April 7, 2025) establishing a closed, regulated supply chain. It prohibits import/export and sales to coffee shops outside participating municipalities.

Notable Quotes

• "Our acquisition of CanAdelaar is a financially compelling and highly strategic transaction that will establish a strategic footprint in Europe and enable us to leverage our investments in borderless products," said Mike Gorenstein, chairman, president and chief executive officer of Cronos.
• "CanAdelaar's management team has rapidly and efficiently scaled the business into a clear market leader in Europe's largest adult-use cannabis market. This makes it an ideal fit for our borderless product strategy as we seek to build upon the strong foundation that CanAdelaar has developed."